PUBLIC COMPANY
saveVaderis Therapeutics AG
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentVaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off. The 13-person Swiss startup raised $152 million in a Series B to run a ...endpoints · 7d ago
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.biopharma_dive · 7d ago
- Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.biospace · 7d ago
- ‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorderVaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rar…fiercebiotech · 8d ago
comments(0)
5-min edit window · permanent after that